RC220
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Key Facts
About Race Oncology
Racura Oncology is advancing RC220, a reformulated version of the anthracene-based drug (E,E)-bisantrene, through three clinical programs in AML, EGFRm NSCLC, and solid tumors. The company's key innovations include the 2025 discovery of its novel MYC-silencing mechanism, enabling new composition-of-matter patents, and the demonstration of cardioprotection when combined with anthracyclines. Operating with a lean, virtual model, Racura's strategy is to progress its clinical portfolio while actively seeking strategic partnerships or M&A to accelerate global commercialization.
View full company profileAbout Racura Oncology
Racura Oncology leverages G‑quadruplex‑binding small molecules to silence MYC and deliver cardioprotective cancer therapy.
View full company profileAbout Racura Oncology
Racura Oncology leverages G‑quadruplex‑binding small molecules to silence MYC and deliver cardioprotective cancer therapy.
View full company profileAbout Racura Oncology
Racura Oncology leverages G‑quadruplex‑binding small molecules to silence MYC and deliver cardioprotective cancer therapy.
View full company profileTherapeutic Areas
Other Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Drugs
| Drug | Company | Phase |
|---|---|---|
| Imetelstat + Azacitidine ± Venetoclax | Geron | Phase 1 |